You just read:

Amygdala Neurosciences Announces Dosing of the First Patient in the NIH Funded Phase 2 Proof-Of-Concept study of ANS-6637 for the Treatment of Alcohol Use Disorder

News provided by

Amygdala Neurosciences Inc.

Oct 17, 2019, 08:37 ET